Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

Introduction

Behavioral and Psychological Symptoms of Dementia (BPSD) pose significant challenges for individuals with dementia and their caregivers. Agitation symptoms, in particular, present a complex management dilemma as there is a lack of consensus regarding pharmacotherapy, specifically with respect to the controversial use of valproate formulations. This study aims to assess the effectiveness of valproate treatment in addressing BPSD, with a specific focus on managing agitation symptoms in individuals with dementia.

Methods

A retrospective analysis was conducted at Peking Union Medical College Hospital (PUMCH) on patients diagnosed with BPSD who received valproate formulations between 2013 and 2023. Patients were classified into 'effective,' 'ineffective,' and 'unknown' groups based on their response to valproate treatment, and the distribution of BPSD symptoms between the effective and ineffective groups was compared.

Results

Among the 116 patients studied, 62.1% exhibited effective responses, 12.1% showed ineffectiveness, and 25.9% had uncertain outcomes with valproate therapy. While the effective group displayed a higher prevalence of agitation symptoms and other behaviors like wandering, restricted and repetitive behaviors, and sleep disturbances compared to the ineffective group, these differences did not reach statistical significance ( = 0.156, 1.000, 0.899, 0.283). Patients in the ineffective group were more likely to experience aggression with comorbid psychotic symptoms compared to those in the effective group ( = 0.023).

Discussion

Valproate may benefit agitation-predominant BPSD without psychosis. Discrepancies in prior findings may stem from differing dosing strategies. Its limited efficacy in psychosis-related aggression underscores the need for careful clinical evaluation.

Conclusion

The findings suggest that tailored valproate treatment at low doses may be beneficial in managing agitation without psychosis in Asian BPSD patients. Further validation through randomized controlled trials is essential to substantiate these observations.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050383192250610115920
2025-06-16
2025-11-07

  • From This Site

    /content/journals/car/10.2174/0115672050383192250610115920
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WattJ.A. PorterJ. TavilsupP. ChowdhuryM. HatchS. IsmailZ. KumarS. KirkhamJ. GoodarziZ. SeitzD. Guideline recommendations on behavioral and psychological symptoms of dementia: A systematic review.J. Am. Med. Dir. Assoc.2024255837846.e2110.1016/j.jamda.2024.03.00738640961
     [Google Scholar]
  2. FinkelS.I. MillerS. SilvaJ.C. CohenG. SartoriusN. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment.Int. Psychogeriatr.19978Suppl. 349750010.1017/S10416102970039439154615
     [Google Scholar]
  3. BaillonS.F. NarayanaU. LuxenbergJ.S. CliftonA.V. Valproate preparations for agitation in dementia.Cochrane Database Syst. Rev.20181010CD00394510.1002/14651858.CD003945.pub430293233
     [Google Scholar]
  4. SanoM. CummingsJ. AuerS. BerghS. FischerC.E. GerritsenD. Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition.Int. Psychogeriatr.202336423825010.1017/S104161022200104136880250
     [Google Scholar]
  5. CummingsJ. SanoM. AuerS. BerghS. FischerC.E. GerritsenD. Reduction and prevention of agitation in persons with neurocognitive disorders: An international psychogeriatric association consensus algorithm.Int. Psychogeriatr.202336425126210.1017/S104161022200103X36876335
     [Google Scholar]
  6. Duff, C. Dementia: Assessment, management and support for people living with dementia and their carers.2018Available from: https://www.nice.org.uk/guidance/ng97
  7. Diagnostic and statistical manual of mental disorders (DSM-5-TR).2013Available from: https://www.psychiatry.org/psychiatrists/practice/dsm
  8. YuE. Chinese guideline of the prevention and treatment of elderly dementia.Beijing People's Medical Publishing House202115235
     [Google Scholar]
  9. TariotP.N. SchneiderL.S. CummingsJ. ThomasR.G. RamanR. JakimovichL.J. LoyR. BartocciB. FleisherA. IsmailM.S. PorsteinssonA. WeinerM. JackC.R.Jr ThalL. AisenP.S. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.Arch. Gen. Psychiatry201168885386110.1001/archgenpsychiatry.2011.7221810649
     [Google Scholar]
  10. GilleyD.W. WilsonR.S. BeckettL.A. EvansD.A. Psychotic symptoms and physically aggressive behavior in Alzheimer’s disease.J. Am. Geriatr. Soc.19974591074107910.1111/j.1532‑5415.1997.tb05969.x9288014
     [Google Scholar]
  11. AarslandD. CummingsJ.L. YennerG. MillerB. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer’s disease.Am. J. Psychiatry1996153224324710.1176/ajp.153.2.2438561206
     [Google Scholar]
  12. PorsteinssonA.P. TariotP.N. ErbR. CoxC. SmithE. JakimovichL. NoviaskyJ. KowalskiN. HoltC.J. IrvineC. Placebo-controlled study of divalproex sodium for agitation in dementia.Am. J. Geriatr. Psychiatry200191586610.1097/00019442‑200102000‑0000911156753
     [Google Scholar]
  13. HerrmannN. LanctôtK.L. RothenburgL.S. EryavecG. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer’s disease.Dement. Geriatr. Cogn. Disord.200723211611910.1159/00009775717148938
     [Google Scholar]
  14. TariotP.N. RamanR. JakimovichL. SchneiderL. PorsteinssonA. ThomasR. MintzerJ. BrennerR. SchaferK. ThalL. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: A randomized, controlled trial.Am. J. Geriatr. Psychiatry2005131194294910.1176/appi.ajgp.13.11.94216286437
     [Google Scholar]
  15. SivalR.C. Judith HaffmansP.M. JansenP.A.F. DuursmaS.A. EikelenboomP. Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial.Int. J. Geriatr. Psychiatry200217657958510.1002/gps.65312112183
     [Google Scholar]
  16. TariotP.N. SchneiderL.S. MintzerJ.E. CutlerA.J. CunninghamM.R. ThomasJ.W. SommervilleK.W. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial.Curr. Ther. Res. Clin. Exp.2001621516710.1016/S0011‑393X(01)80042‑4
     [Google Scholar]
  17. LindleyR.I. Do valproate preparations improve agitation in dementia? A cochrane review summary with commentary.Australas. J. Ageing202140333633810.1111/ajag.1298434390114
     [Google Scholar]
  18. LiuJ. WangL. Efficacy and safety of valproic acid in dementia: A systematic review with meta-analysis.Arch. Gerontol. Geriatr.20208910409110.1016/j.archger.2020.10409132413690
     [Google Scholar]
  19. DolderC. MckinseyJ. Low-dose divalproex in agitated patients with Alzheimer’s disease.J. Psychiatr. Pract.2010161636710.1097/01.pra.0000367781.26507.8620098234
     [Google Scholar]
  20. ForesterB. VanelliM. HydeJ. PerezR. AhokpossiC. SribneyW. AdkisonL. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.Am. J. Geriatr. Pharmacother.20075320921710.1016/j.amjopharm.2007.09.00117996660
     [Google Scholar]
  21. SivalR.C. DuivenvoordenH.J. JansenP.A.F. HaffmansP.M.J. DuursmaS.A. EikelenboomP. Sodium valproate in aggressive behaviour in dementia: A twelve-week open label follow-up study.Int. J. Geriatr. Psychiatry200419430531210.1002/gps.103415065222
     [Google Scholar]
  22. PorsteinssonA.P. TariotP.N. JakimovichL.J. KowalskiN. HoltC. ErbR. CoxC. Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial.Am. J. Geriatr. Psychiatry200311443444010.1097/00019442‑200307000‑0000612837672
     [Google Scholar]
  23. HerrmannN. Valproic acid treatment of agitation in dementia.Can. J. Psychiatry1998431697210.1177/0706743798043001089494750
     [Google Scholar]
  24. DolderC.R. NealyK.L. McKinseyJ. Valproic acid in dementia: Does an optimal dose exist?J. Pharm. Pract.201225214215010.1177/089719001142480222095580
     [Google Scholar]
  25. FrederiksenK.S. CooperC. FrisoniG.B. FrölichL. GeorgesJ. KrambergerM.G. NilssonC. PassmoreP. Mantoan RitterL. ReligaD. SchmidtR. StefanovaE. VerdelhoA. VandenbulckeM. WinbladB. WaldemarG. A European Academy of Neurology guideline on medical management issues in dementia.Eur. J. Neurol.202027101805182010.1111/ene.1441232713125
     [Google Scholar]
  26. ShajiK.S. SivakumarP.T. RaoG.P. PaulN. Clinical practice guidelines for management of dementia.Indian J. Psychiatry2018607Suppl. 331210.4103/0019‑5545.22447229535467
     [Google Scholar]
  27. ReusV.I. FochtmannL.J. EylerA.E. HiltyD.M. Horvitz-LennonM. JibsonM.D. LopezO.L. MahoneyJ. PasicJ. TanZ.S. WillsC.D. RhoadsR. YagerJ. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.Focus Am. Psychiatr. Publ.2017151818410.1176/appi.focus.1510731997967
     [Google Scholar]
  28. MasopustJ. ProtopopováD. VališM. PavelekZ. KlímováB. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: A review.Neuropsychiatr. Dis. Treat.2018141211122010.2147/NDT.S16384229785112
     [Google Scholar]
  29. ZhangC. SunL. SunH. Effects of magnesium valproate adjuvant therapy on patients with dementia: A systematic review and meta-analysis.Medicine202210131e2964210.1097/MD.000000000002964235945786
     [Google Scholar]
  30. BjerreL.M. FarrellB. HogelM. GrahamL. LemayG. McCarthyL. Raman-WilmsL. Rojas-FernandezC. SinhaS. ThompsonW. WelchV. WiensA. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.Can. Fam. Physician2018641172729358245
     [Google Scholar]
  31. ReusV.I. FochtmannL.J. EylerA.E. HiltyD.M. Horvitz-LennonM. JibsonM.D. LopezO.L. MahoneyJ. PasicJ. TanZ.S. WillsC.D. RhoadsR. YagerJ. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.Am. J. Psychiatry2016173554354610.1176/appi.ajp.2015.17350127133416
     [Google Scholar]
  32. SorbiS. HortJ. ErkinjunttiT. FladbyT. GainottiG. GurvitH. NacmiasB. PasquierF. PopescuB.O. RektorovaI. ReligaD. RusinaR. RossorM. SchmidtR. StefanovaE. WarrenJ.D. ScheltensP. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.Eur. J. Neurol.20121991159117910.1111/j.1468‑1331.2012.03784.x22891773
     [Google Scholar]
  33. McShaneR. WestbyM.J. RobertsE. MinakaranN. SchneiderL. FarrimondL.E. MaayanN. WareJ. DebarrosJ. Memantine for dementia.Cochrane Database Syst. Rev.201933CD00315410.1002/14651858.CD003154.pub630891742
     [Google Scholar]
  34. ChenR. ChanP.T. ChuH. LinY.C. ChangP.C. ChenC.Y. ChouK.R. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.PLoS One2017128e018358610.1371/journal.pone.018358628827830
     [Google Scholar]
/content/journals/car/10.2174/0115672050383192250610115920
Loading
Efficacy of Sodium Valproate in Behavioral and Psychological Symptoms of Dementia: A Retrospective Observational Study from PUMCH Dementia Cohort
Curr Alzheimer Res 22, 376 (2025); https://doi.org/10.2174/0115672050383192250610115920
/content/journals/car/10.2174/0115672050383192250610115920
/content/journals/car/10.2174/0115672050383192250610115920
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): aberrant motor behavior in dementia; aggression; behavioral and psychological symptoms; Dementia; dementia agitation; psychomotor agitation; valproic acid

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test